显示样式:     当前期刊: JAMA Psychiatry    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Pediatric Use of Antipsychotic Medications Before and After Medicaid Peer Review Implementation
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-15
    Julie M. Zito, Mehmet Burcu, Stephen McKean, Rob Warnock, Jeffrey Kelman
    更新日期:2017-11-16
  • Association of Obsessive-Compulsive Disorder With Objective Indicators of Educational AttainmentA Nationwide Register-Based Sibling Control Study
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-15
    Ana Pérez-Vigil, Lorena Fernández de la Cruz, Gustaf Brander, Kayoko Isomura, Andreas Jangmo, Inna Feldman, Eva Hesselmark, Eva Serlachius, Luisa Lázaro, Christian Rück, Ralf Kuja-Halkola, Brian M. D’Onofrio, Henrik Larsson, David Mataix-Cols
    更新日期:2017-11-16
  • Concurrent and Longitudinal Contribution of Exposure to Bullying in Childhood to Mental HealthThe Role of Vulnerability and Resilience
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Timothy Singham, Essi Viding, Tabea Schoeler, Louise Arseneault, Angelica Ronald, Charlotte M. Cecil, Eamon McCrory, Frülhing Rijsdijk, Jean-Baptiste Pingault
    更新日期:2017-11-10
  • Causal and Noncausal Processes Underlying Being Bullied
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Judy Silberg, Kenneth S. Kendler

    Nearly 1 in 5 children have been bullied by peers.2 No longer considered a normative behavior of childhood, being bullied by a peer is a major risk factor for a wide spectrum of adverse outcomes in children.3 The rising number of suicides and violence among children who have been bullied makes understanding the causal processes a high priority. Internalizing behaviors, externalizing problems, poor school performance, somatization, and low self-esteem are some of the commonly reported difficulties in children who are bullied. However, the problems are not limited to childhood. Population-based studies demonstrate an enduring effect on mental health outcomes in adulthood long after the bullying has stopped.4 Despite these demonstrable associations, it is not known to what extent bullying and mental health are causally linked.

    更新日期:2017-11-10
  • Association of Genetic Risk for Schizophrenia and Bipolar Disorder With Infant Neuromotor Development
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-08
    Fadila Serdarevic, Philip R. Jansen, Akhgar Ghassabian, Tonya White, Vincent W. V. Jaddoe, Danielle Posthuma, Henning Tiemeier
    更新日期:2017-11-10
  • Effectiveness of Online Collaborative Care for Treating Mood and Anxiety Disorders in Primary CareA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-08
    Bruce L. Rollman, Bea Herbeck Belnap, Kaleab Z. Abebe, Michael B. Spring, Armando J. Rotondi, Scott D. Rothenberger, Jordan F. Karp
    更新日期:2017-11-10
  • Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective DisorderA Genome-Wide Association Study
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-09
    Azmeraw T. Amare, Klaus Oliver Schubert, Liping Hou, Scott R. Clark, Sergi Papiol, Urs Heilbronner, Franziska Degenhardt, Fasil Tekola-Ayele, Yi-Hsiang Hsu, Tatyana Shekhtman, Mazda Adli, Nirmala Akula, Kazufumi Akiyama, Raffaella Ardau, Bárbara Arias, Jean-Michel Aubry, Lena Backlund, Abesh Kumar Bhattacharjee, Frank Bellivier, Antonio Benabarre, Susanne Bengesser, Joanna M. Biernacka, Armin Birner, Clara Brichant-Petitjean, Pablo Cervantes, Hsi-Chung Chen, Caterina Chillotti, Sven Cichon, Cristiana Cruceanu, Piotr M. Czerski, Nina Dalkner, Alexandre Dayer, Maria Del Zompo, J. Raymond DePaulo, Bruno Étain, Peter Falkai, Andreas J. Forstner, Louise Frisen, Mark A. Frye, Janice M. Fullerton, Sébastien Gard, Julie S. Garnham, Fernando S. Goes, Maria Grigoroiu-Serbanescu, Paul Grof, Ryota Hashimoto, Joanna Hauser, Stefan Herms, Per Hoffmann, Andrea Hofmann, Stephane Jamain, Esther Jiménez, Jean-Pierre Kahn, Layla Kassem, Po-Hsiu Kuo, Tadafumi Kato, John Kelsoe, Sarah Kittel-Schneider, Sebastian Kliwicki, Barbara König, Ichiro Kusumi, Gonzalo Laje, Mikael Landén, Catharina Lavebratt, Marion Leboyer, Susan G. Leckband, Alfonso Tortorella, Mirko Manchia, Lina Martinsson, Michael J. McCarthy, Susan McElroy, Francesc Colom, Marina Mitjans, Francis M. Mondimore, Palmiero Monteleone, Caroline M. Nievergelt, Markus M. Nöthen, Tomas Novák, Claire O’Donovan, Norio Ozaki, Urban Ösby, Andrea Pfennig, James B. Potash, Andreas Reif, Eva Reininghaus, Guy A. Rouleau, Janusz K. Rybakowski, Martin Schalling, Peter R. Schofield, Barbara W. Schweizer, Giovanni Severino, Paul D. Shilling, Katzutaka Shimoda, Christian Simhandl, Claire M. Slaney, Alessio Squassina, Thomas Stamm, Pavla Stopkova, Mario Maj, Gustavo Turecki, Eduard Vieta, Julia Volkert, Stephanie Witt, Adam Wright, Peter P. Zandi, Philip B. Mitchell, Michael Bauer, Martin Alda, Marcella Rietschel, Francis J. McMahon, Thomas G. Schulze, Bernhard T. Baune
    更新日期:2017-11-10
  • JAMA Psychiatry
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01

    Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform and to educate its readers as well as to stimulate debate and further exploration into the nature, causes, treatment, and public health importance of mental illness. The JAMA Network is a consortium of peer-reviewed print and online medical publications that includes JAMA®, JAMA Psychiatry, and other specialty journals. JAMA Psychiatry does not hold itself responsible for statements made by any contributor. All articles published, including opinion articles, represent the views of the authors and do not reflect the policy of the Journal, the American Medical Association, or the institution with which the author is affiliated, unless otherwise indicated.

    更新日期:2017-11-01
  • Correction of Misspelled Author Name
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01

    In the Original Investigation titled “Developmental Trajectories of Impaired Community Functioning in Schizophrenia,” published in the January 2016 issue of JAMA Psychiatry,1 the surname of one of the authors was misspelled in the byline, Author Affiliations, and Author Contributions. The third author’s name was given as “Ori Kapara, BA,” but should have appeared as “Ori Kapra, BA.” This article was corrected online.

    更新日期:2017-11-01
  • Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Anders Fink-Jensen, Christoph U. Correll, Tina Vilsbøll

    In Reply We thank Deutch for his thoughtful response to our study,1 in which we reported that the glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces body weight, improves glucose tolerance, and decreases systolic blood pressure in patients with schizophrenia receiving clozapine or olanzapine. Deutch correctly pointed out that GLP-1 receptor stimulation can dampen activation of the reward pathways (eg, reduction of cocaine-induced dopamine elevation2) and therefore suggested that a detailed assessment of liraglutide-induced psychiatric symptoms, particularly the so-called negative symptoms, such as anhedonia and blunted affect, should be performed before GLP-1 receptor agonists are used to counter antipsychotic-induced body weight gain and metabolic disturbances.

    更新日期:2017-11-01
  • Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Ariel Y. Deutch

    To the Editor Treatment with certain antipsychotic drugs (APDs) causes weight gain, leading to metabolic syndrome and increasing cardiovascular-associated mortality. Although several pharmacologic agents and some behavioral interventions attenuate APD-elicited weight gain, the effects are modest and rarely reduce body weight to baseline levels. In JAMA Psychiatry, Larsen et al1 report that the antidiabetic agent liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces body weight, improves glucose tolerance, and decreases systolic blood pressure in patients with schizophrenia receiving clozapine or olanzapine, 2 APDs with high weight-gain liability. The magnitude of weight loss seen in response to liraglutide in APD-treated patients with schizophrenia was consistent with previous studies of liraglutide in patients with type 2 diabetes and in patients without diabetes and with obesity, despite administration of a relatively low dose (1.8 mg) of liraglutide. Liraglutide-elicited weight loss was somewhat greater than that reported in studies of metformin, a biguanide antidiabetic agent used to attenuate APD-elicited weight gain. Liraglutide is potentially an important addition to the therapeutic armamentarium for APD-elicited weight gain and associated metabolic and cardiovascular changes.

    更新日期:2017-11-01
  • Factors to Consider for Reducing US Opioid-Related Deaths: Looking Beyond Access
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Nitigna Desai, Shane W. Kraus, Joseph R. Houchins

    To the Editor We want to thank Martins et al1 for their direction as we attempt to navigate and remap the current opioid epidemic’s vexing domestic landscape. As Martins et al1 reported, there was a 5-fold increase in heroin use and 3-fold increase in heroin use disorders from 2001 to 2013, which have likely contributed to the rise of US opioid-related deaths (ORDs) since 2002.2 One of the primary responses to the opioid crisis was increasing access to opioid-dependency medications, including buprenorphine, by increasing the number of prescribers.3 To explore the effectiveness of this intervention on ORDs in Massachusetts, we examined the number of buprenorphine prescribers and ORDs from 2010 to 2016.

    更新日期:2017-11-01
  • Factors to Consider for Reducing US Opioid-Related Deaths: Looking Beyond Access—ReplyFactors to Consider for Reducing US Opioid-Related Deaths—Reply
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Silvia S. Martins, Julian Santaella-Tenorio, Deborah S. Hasin

    In Reply We thank Desai et al for commenting on our article1 reporting trends in heroin use and heroin use disorder in the United States and for noting their findings that while access to opioid-dependency medication (ODM) increased in Massachusetts from 2010 to 2016 through greater numbers of ODM prescribers, opioid-related deaths rose even faster. Clearly, increasing the number of available ODM prescribers is only 1 of many factors that must be addressed to solve the opioid epidemic. We agree with Desai et al that despite the benefits of ODM among those receiving it, rates of opioid-related deaths are not likely to decrease if the incidence and prevalence of heroin use and other opioids (eg, fentanyl and even stronger synthetic opioids) continue to rise. Further, we note that prescribers are usually limited in the number of patients to whom they can offer ODM, so an increase in prescribers does not necessarily translate into a sharp increase in the number of patients receiving ODM. Moreover, only a minority of patients with opioid use disorder seek treatment because of stigma, beliefs that they do not need treatment, or structural barriers/accessibility to seek treatment after being treated for an opioid overdose.2 Of those who do, many drop out.3

    更新日期:2017-11-01
  • Corollary Discharge, Self-agency, and the Neurodevelopment of the Psychotic Mind
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Michele Poletti, Eva Gebhardt, Andrea Raballo
    更新日期:2017-11-01
  • Association Between Mitochondrial DNA Haplogroup Variation and Autism Spectrum Disorders
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Dimitra Chalkia, Larry N. Singh, Jeremy Leipzig, Maria Lvova, Olga Derbeneva, Anita Lakatos, Dexter Hadley, Hakon Hakonarson, Douglas C. Wallace
    更新日期:2017-11-01
  • Polygenic Scores for Major Depressive Disorder and Risk of Alcohol Dependence
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Allan M. Andersen, Robert H. Pietrzak, Henry R. Kranzler, Li Ma, Hang Zhou, Xiaoming Liu, John Kramer, Samuel Kuperman, Howard J. Edenberg, John I. Nurnberger, John P. Rice, Jay A. Tischfield, Alison Goate, Tatiana M. Foroud, Jacquelyn L. Meyers, Bernice Porjesz, Danielle M. Dick, Victor Hesselbrock, Eric Boerwinkle, Steven M. Southwick, John H. Krystal, Myrna M. Weissman, Douglas F. Levinson, James B. Potash, Joel Gelernter, Shizhong Han
    更新日期:2017-11-01
  • Association of Panic Disorder, Generalized Anxiety Disorder, and Benzodiazepine Treatment During Pregnancy With Risk of Adverse Birth Outcomes
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Kimberly Ann Yonkers, Kathryn Gilstad-Hayden, Ariadna Forray, Heather S. Lipkind
    更新日期:2017-11-01
  • Association Between Psychotic Experiences and Subsequent Suicidal Thoughts and BehaviorsA Cross-National Analysis From the World Health Organization World Mental Health Surveys
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Evelyn J. Bromet, Matthew K. Nock, Sukanta Saha, Carmen C. W. Lim, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Guilherme Borges, Ronny Bruffaerts, Louisa Degenhardt, Giovanni de Girolamo, Peter de Jonge, Silvia Florescu, Oye Gureje, Josep M. Haro, Yanling He, Chiyi Hu, Elie G. Karam, Viviane Kovess-Masfety, Sing Lee, Jean-Pierre Lepine, Zeina Mneimneh, Fernando Navarro-Mateu, Akin Ojagbemi, José Posada-Villa, Nancy A. Sampson, Kate M. Scott, Juan C. Stagnaro, Maria C. Viana, Miguel Xavier, Ronald C. Kessler, John J. McGrath
    更新日期:2017-11-01
  • Adherence to Depression Treatment in Primary CareA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Jo Anne Sirey, Samprit Banerjee, Patricia Marino, Martha L. Bruce, Ashley Halkett, Molly Turnwald, Claire Chiang, Brian Liles, Amanda Artis, Fred Blow, Helen C. Kales
    更新日期:2017-11-01
  • Association of White Matter Structure With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Yuta Aoki, Yuliya N. Yoncheva, Bosi Chen, Tanmay Nath, Dillon Sharp, Mariana Lazar, Pablo Velasco, Michael P. Milham, Adriana Di Martino
    更新日期:2017-11-01
  • Heterogeneity and Homogeneity of Regional Brain Structure in SchizophreniaA Meta-analysis
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Stefan P. Brugger, Oliver D. Howes
    更新日期:2017-11-01
  • National Trends in Suicide Attempts Among Adults in the United States
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Mark Olfson, Carlos Blanco, Melanie Wall, Shang-Min Liu, Tulshi D. Saha, Roger P. Pickering, Bridget F. Grant
    更新日期:2017-11-01
  • Heterogeneity Within and Between Autism Spectrum Disorder and Attention-Deficit/Hyperactivity DisorderChallenge or Opportunity?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Stephanie H. Ameis

    Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are common neurodevelopmental disorders (NDDs), categorized separately in the DSM-5 and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Yet, there are significant clinical and neurobiological similarities among children with either ASD or ADHD. Considerable clinical and neurobiological heterogeneity within disorders is also present. The etiology of either ASD or ADHD remains unclear, although perturbation in large-scale neural connectivity has been implicated across disorders based on the association of genes that regulate neural migration and synaptic development with both disorders1 and case-control neuroimaging studies that demonstrated altered structural and functional connectivity across several neural networks in either disorder, compared with typically developing controls (TDCs). Although neuroscience research has provided important clues regarding neurodevelopmental alterations present in ASD and ADHD, findings that are inconsistent and nonspecific to either NDD limit the opportunities for clinical translation.

    更新日期:2017-11-01
  • Parsing Heterogeneity
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Stephen M. Lawrie

    It is commonplace for researchers to invoke the heterogeneity of psychiatric disorders as an explanation as to why the results of their study differ from others. It is quite common to hear suggestions that heterogeneity is a particular problem in psychiatry. To my knowledge, that statement has no evidence to support it. Heterogeneity is ubiquitous in medicine. Sampling biases, methodological variabilities, insufficient power, and differential confounding are the most likely explanations for disagreements between studies. If these can be confidently excluded and true rather than artifactual heterogeneity across a population be proven, an explanation of that is required. Population stratification represents the most scientifically tractable approach to teasing out meaning from the morass of data. Clinically, the most useful response would be subtyping by biomarkers that have practical use.

    更新日期:2017-11-01
  • 更新日期:2017-11-01
  • Highlights
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01

    Suicides have increased in the United States, but trends among sociodemographic and clinical groups have not been characterized. Using nationally representative survey data, Olfson and colleagues found that the percentage of adults making a recent suicide attempt increased from 0.62% in 2004/2005 to 0.79% in 2012/2013. The increase in risk was significantly larger among younger adults and among adults with no more than a high school education. In an Editorial, Caine discusses implications for suicide research.

    更新日期:2017-11-01
  • Inflammatory Biomarkers and Risk of SchizophreniaA 2-Sample Mendelian Randomization Study
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Fernando Pires Hartwig, Maria Carolina Borges, Bernardo Lessa Horta, Jack Bowden, George Davey Smith
    更新日期:2017-11-01
  • Inference in Psychiatry via 2-Sample Mendelian Randomization—From Association to Causal Pathway?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Enda M. Byrne, Jian Yang, Naomi R. Wray

    A key goal of psychiatric epidemiology is to identify causal risk factors for psychiatric disorders that, when modified through an intervention, will lower incidence of disease and decrease burdens of symptoms in patients with the disease. Observational studies have identified several potential risk factors that are associated with mental illness, but identifying those that are causal rather than associated is challenging because of confounding, selection bias, reverse causation, or pleiotropy (ie, a single gene may influence multiple unrelated phenotypic traits).

    更新日期:2017-11-01
  • Evidence-Based Pragmatic Psychiatry—A Call to Action
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-11-01
    Martin P. Paulus
    更新日期:2017-11-01
  • 更新日期:2017-11-01
  • Error in Results
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-25

    In the Original Investigation titled “The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-report Screening Scale for DSM-5,”1 published online April 5, 2017, and in the May 2017 print issue, there was an error in the Results section of the article. In the second paragraph of “Choosing the Optimal Number of Screening Questions,” option 3 included the phrase “Criterion A2e, acts as if ‘driven by a motor.’” The phrase should have been “Criterion A2d, difficulty playing quietly/leisure time.” This article was corrected online.

    更新日期:2017-10-26
  • Extent of Dorsolateral Prefrontal Cortex Plasticity and Its Association With Working Memory in Patients With Alzheimer Disease
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-25
    Sanjeev Kumar, Reza Zomorrodi, Zaid Ghazala, Michelle S. Goodman, Daniel M. Blumberger, Amay Cheam, Corinne Fischer, Zafiris J. Daskalakis, Benoit H. Mulsant, Bruce G. Pollock, Tarek K. Rajji
    更新日期:2017-10-26
  • Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-25
    Hang Zhou, Renato Polimanti, Bao-Zhu Yang, Qian Wang, Shizhong Han, Richard Sherva, Yaira Z. Nuñez, Hongyu Zhao, Lindsay A. Farrer, Henry R. Kranzler, Joel Gelernter
    更新日期:2017-10-26
  • Challenges in the Study of Genetic Variants of Comorbid Alcohol Use Disorder and Major Depression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-25
    Alexis C. Edwards

    Alcohol use disorder (AUD) and major depressive disorder (MDD) are common psychiatric disorders associated with substantial social and economic costs. It has long been acknowledged that these disorders co-occur more frequently than would be expected by chance, but mechanisms underlying this comorbidity are unclear. Khantzian et al1 have proposed that alcohol use to self-medicate negative affect plays a role in the observed association; other evidence suggests causation in the opposite direction,2 with AUD increasing one’s risk of MDD, potentially through the neurobiological consequences of sustained heavy alcohol consumption. Biometric models suggest shared liability between disorders,3 in that a subset of factors influencing liability to one disorder independently influences liability to the other. These mechanisms are not mutually exclusive, even within an individual, although their implications for prevention, intervention, and treatment differ.

    更新日期:2017-10-26
  • The Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid DependenceA Randomized Clinical Noninferiority Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-18
    Lars Tanum, Kristin Klemmetsby Solli, Zill-e-Huma Latif, Jūratė Šaltytė Benth, Arild Opheim, Kamni Sharma-Haase, Peter Krajci, Nikolaj Kunøe
    更新日期:2017-10-18
  • Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-18
    Yuri Milaneschi, Femke Lamers, Wouter J. Peyrot, Bernhard T. Baune, Gerome Breen, Abbas Dehghan, Andreas J. Forstner, Hans J. Grabe, Georg Homuth, Carol Kan, Cathryn Lewis, Niamh Mullins, Matthias Nauck, Giorgio Pistis, Martin Preisig, Margarita Rivera, Marcella Rietschel, Fabian Streit, Jana Strohmaier, Alexander Teumer, Sandra Van der Auwera, Naomi R. Wray, Dorret I. Boomsma, Brenda W. J. H. Penninx
    更新日期:2017-10-18
  • Leveraging Molecular Genetic Approaches to Yield Insights Into Major Depression Etiology and Clinical Presentation
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-18
    Roseann E. Peterson

    Major depressive disorder (MDD) is an important public health concern and is often comorbid with other serious medical conditions, such as obesity, cardiovascular disease, and type 2 diabetes.1 Notably, several symptoms of MDD are related to energy balance, including disturbances in weight, appetite, and sleep. Genetic factors have consistently been demonstrated to influence individual differences in MDD and body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), with twin studies estimating heritabilities (h2) on the order of 0.37 and 0.70, respectively.2,3 Despite numerous associations between MDD, BMI, and obesity, there has been surprisingly limited research on shared genetic liability.

    更新日期:2017-10-18
  • Mood Instability and Reward Dysregulation—A Neurocomputational Model of Bipolar Disorder
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-11
    Liam Mason, Eran Eldar, Robb B. Rutledge
    更新日期:2017-10-11
  • A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-11
    Sameer Jauhar, Matthew M. Nour, Mattia Veronese, Maria Rogdaki, Ilaria Bonoldi, Matilda Azis, Federico Turkheimer, Philip McGuire, Allan H. Young, Oliver D. Howes
    更新日期:2017-10-11
  • Dopamine Dysfunction in Schizophrenia and Bipolar Disorder—Never the Twain Shall Meet?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-11
    Dost Öngür

    German psychiatrist Emil Kraepelin (1856-1926) was one of the first to make a prominent distinction between dementia praecox (roughly corresponding to schizophrenia) with its “irreversible dementing cortical disturbances” and manic-depressive insanity (roughly corresponding to bipolar disorder, especially with psychosis), from which patients “recover with their personality intact.”1(p28) Toward the end of his career, Kraepelin acknowledged that “there is an alarmingly large number of cases in which it seems impossible, in spite of the most careful observation, to make a firm diagnosis.”1(p28) Indeed, most patients with psychotic disorders show complex clinical presentations not conforming to classic descriptions of either disorder. Since Kraepelin’s time, there has been great interest in identifying features that distinguish schizophrenia from bipolar disorder because prognosis and treatment approaches differ between the two. To date, the results have been mixed at best. It appears that these disease categories are not completely distinct, although boundaries between them can occasionally be detected using clinical and biological measures (eg, as described by Kotov et al2 and Grozeva et al3).

    更新日期:2017-10-11
  • Death by Gun Violence—A Public Health Crisis
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-09
    Howard Bauchner, Frederick P. Rivara, Robert O. Bonow, Neil M. Bressler, Mary L. (Nora) Disis, Stephan Heckers, S. Andrew Josephson, Melina R. Kibbe, Jay F. Piccirillo, Rita F. Redberg, John S. Rhee, June K. Robinson

    The shooting in Las Vegas, Nevada, that left 59 people dead, 10 times that number wounded, and thousands of people with the psychological distress from being present at the scene during and after the massacre has once again raised the issue of what we as a nation can and should do about guns. The solution lies in not just focusing on Las Vegas and the hundreds of other mass shootings that have occurred in the United States in the last 14 months, but rather to underscore that on average almost 100 people die each day in the United States from gun violence. The 36 252 deaths from firearms in the United States in 20151 exceeded the number of deaths from motor vehicle traffic crashes that year (36 161).1 That same year, the US Centers for Disease Control and Prevention reported that 5 people died from terrorism. Since 1968, more individuals in the United States have died from gun violence than in battle during all the wars the country has fought since its inception.2

    更新日期:2017-10-09
  • JAMA Psychiatry
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01

    Mission Statement: JAMA Psychiatry strives to publish original, state-of-the-art studies and commentaries of general interest to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and allied fields. The journal seeks to inform and to educate its readers as well as to stimulate debate and further exploration into the nature, causes, treatment, and public health importance of mental illness. The JAMA Network is a consortium of peer-reviewed print and online medical publications that includes JAMA®, JAMA Psychiatry, and other specialty journals. JAMA Psychiatry does not hold itself responsible for statements made by any contributor. All articles published, including opinion articles, represent the views of the authors and do not reflect the policy of the Journal, the American Medical Association, or the institution with which the author is affiliated, unless otherwise indicated.

    更新日期:2017-10-06
  • Error on X-axes in Figure 2
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01

    In the Article titled “Changes in US Lifetime Heroin Use and Heroin Use Disorder: Prevalence From the 2001-2002 to 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions,”1 published online March 29, 2017, on the x-axes in Figure 2, the years for the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) III should be 2012-2013.

    更新日期:2017-10-06
  • Errors in Results and Tables
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01

    In the Original Investigation titled “Structural and Functional Brain Abnormalities in Attention-Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder: a Comparative Meta-Analysis,”1 published online June 8, 2016, and also in the August 2016 print issue of JAMA Psychiatry, there were errors in the reporting of the results. The correct numbers of patients with attention-deficit/hyperactivity disorder and healthy controls included in the attention-deficit/hyperactivity disorder functional magnetic resonance imaging meta-analysis are 541 and 620, respectively. These values are given in Table 1, but incorrect numbers were included in text in the abstract and Results section. Moreover, the correct number of controls in the obsessive-compulsive disorder functional magnetic resonance imaging studies is 284. Finally, the cluster given in Table 2 as “(28, 4, 2)” should be given as “(−28, 4, 2).” None of the findings from this article are affected by these errors. This article was corrected online.

    更新日期:2017-10-06
  • 更新日期:2017-10-06
  • The Benefits of Purposeful Life Engagement on Later-Life Physical Function
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Carol D. Ryff

    Although psychological disorders, such as depression and anxiety, have long been studied as factors that contribute to poorer health (broadly defined) over time, it is only in the last few years that psychological strengths have emerged as having possible protective influences on health. One such strength is purpose in life, which was first formulated from the life experiences of Victor Frankl, who spent 3 years in a Nazi concentration camp.1 He saw purpose in life as having life-saving features and went on to develop a form of psychotherapy based on it. What does purpose in life mean? It is about reflective activities in which individuals perceive their existence to be meaningful and to include goals for which they live. Sometimes, this takes proactive efforts. In 1989, I developed a structured, self-report scale to measure purpose in life,2 along with 5 other dimensions of psychological well-being. Since then, more than 500 publications have grown up around this model of well-being. Components of it have been linked to a host of other domains (aging, work and family life, personality, health, and interventions).3 However, without question, the greatest amount of new science that has taken well-being in the direction of health has involved purpose in life. Frankl, a psychiatrist by training, saw it was essential for sustaining life, particularly under conditions of adversity. A growing body of evidence suggests he was probably right.

    更新日期:2017-10-06
  • Prevention of Anxiety Disorders Across the Lifespan
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Jennifer L. Hudson

    Anxiety disorders are the most common mental disorders across the lifespan and exact a massive disease burden.1 Anxiety disorders typically onset in childhood and predict a range of later mental health problems, such as depression, suicide, and substance abuse. Despite this, anxiety disorders are frequently underrecognized and overlooked as serious mental health problems. There are a number of factors that influence the limited attention anxiety disorders receive, both in terms of clinical practice and public health policy. The reduced focus is likely in part because of poor mental health literacy. There is a common misconception that anxiety disorders are reserved for the “worried well” and represent a personality flaw rather than a disorder. In addition, anxiety itself is a normal emotion, perhaps leading to misunderstanding surrounding the difference between normal and pathological fear and anxiety. The transient nature of some fears in early childhood may also lead to a misconception that the disorder will remit with time or maturation. For most individuals, anxiety disorders are relatively stable, long-term, and disabling and need to be taken seriously.

    更新日期:2017-10-06
  • Identification of Genetic Loci Jointly Influencing Schizophrenia Risk and the Cognitive Traits of Verbal-Numerical Reasoning, Reaction Time, and General Cognitive Function
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Olav B. Smeland, Oleksandr Frei, Karolina Kauppi, W. David Hill, Wen Li, Yunpeng Wang, Florian Krull, Francesco Bettella, Jon A. Eriksen, Aree Witoelar, Gail Davies, Chun C. Fan, Wesley K. Thompson, Max Lam, Todd Lencz, Chi-Hua Chen, Torill Ueland, Erik G. Jönsson, Srdjan Djurovic, Ian J. Deary, Anders M. Dale, Ole A. Andreassen
    更新日期:2017-10-06
  • Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Stephen T. Higgins, Sarah H. Heil, Stacey C. Sigmon, Jennifer W. Tidey, Diann E. Gaalema, John R. Hughes, Maxine L. Stitzer, Hanna Durand, Janice Y. Bunn, Jeff S. Priest, Christopher A. Arger, Mollie E. Miller, Cecilia L. Bergeria, Danielle R. Davis, Joanna M. Streck, Derek D. Reed, Joan M. Skelly, Lauren Tursi
    更新日期:2017-10-06
  • Association of Risk of Suicide Attempts With Methylphenidate Treatment
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Kenneth K. C. Man, David Coghill, Esther W. Chan, Wallis C. Y. Lau, Chris Hollis, Elizabeth Liddle, Tobias Banaschewski, Suzanne McCarthy, Antje Neubert, Kapil Sayal, Patrick Ip, Martijn J. Schuemie, Miriam C. J. M. Sturkenboom, Edmund Sonuga-Barke, Jan Buitelaar, Sara Carucci, Alessandro Zuddas, Hanna Kovshoff, Peter Garas, Peter Nagy, Sarah K. Inglis, Kerstin Konrad, Alexander Häge, Eric Rosenthal, Ian C. K. Wong
    更新日期:2017-10-06
  • Association Between Purpose in Life and Objective Measures of Physical Function in Older Adults
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Eric S. Kim, Ichiro Kawachi, Ying Chen, Laura D. Kubzansky
    更新日期:2017-10-06
  • Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Alexander Viktorin, Rudolf Uher, Alexander Kolevzon, Abraham Reichenberg, Stephen Z. Levine, Sven Sandin
    更新日期:2017-10-06
  • Effectiveness of Psychological and/or Educational Interventions in the Prevention of AnxietyA Systematic Review, Meta-analysis, and Meta-regression
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Patricia Moreno-Peral, Sonia Conejo-Cerón, Maria Rubio-Valera, Anna Fernández, Desirée Navas-Campaña, Alberto Rodríguez-Morejón, Emma Motrico, Alina Rigabert, Juan de Dios Luna, Carlos Martín-Pérez, Antonina Rodríguez-Bayón, María Isabel Ballesta-Rodríguez, Juan Vicente Luciano, Juan Ángel Bellón
    更新日期:2017-10-06
  • Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and AdolescentsA Systematic Review and Meta-analysis
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Cosima Locher, Helen Koechlin, Sean R. Zion, Christoph Werner, Daniel S. Pine, Irving Kirsch, Ronald C. Kessler, Joe Kossowsky
    更新日期:2017-10-06
  • Association of Lithium in Drinking Water With the Incidence of Dementia
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Lars Vedel Kessing, Thomas Alexander Gerds, Nikoline Nygård Knudsen, Lisbeth Flindt Jørgensen, Søren Munch Kristiansen, Denitza Voutchkova, Vibeke Ernstsen, Jörg Schullehner, Birgitte Hansen, Per Kragh Andersen, Annette Kjær Ersbøll
    更新日期:2017-10-06
  • Effectiveness and Safety of Dementia Care Management in Primary CareA Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Jochen René Thyrian, Johannes Hertel, Diana Wucherer, Tilly Eichler, Bernhard Michalowsky, Adina Dreier-Wolfgramm, Ina Zwingmann, Ingo Kilimann, Stefan Teipel, Wolfgang Hoffmann
    更新日期:2017-10-06
  • Effect of Internet-Based Guided Self-help vs Individual Face-to-Face Treatment on Full or Subsyndromal Binge Eating Disorder in Overweight or Obese PatientsThe INTERBED Randomized Clinical Trial
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Martina de Zwaan, Stephan Herpertz, Stephan Zipfel, Jennifer Svaldi, Hans-Christoph Friederich, Frauke Schmidt, Andreas Mayr, Tony Lam, Carmen Schade-Brittinger, Anja Hilbert
    更新日期:2017-10-06
  • Effectiveness and Safety of Antidepressants for Children and AdolescentsImplications for Clinical Practice
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    Sally Nicola Merry, Sarah Elisabeth Hetrick, Karolina Stasiak

    It is now well understood that disorders of anxiety and depression in children and adolescents are common, debilitating, and largely undetected and untreated.1 The mainstays of treatment include psychological therapy, predominantly cognitive behavioral therapy, and medication, usually antidepressants, which, despite their name, are also used for anxiety disorders and obsessive-compulsive disorder.2 In this issue of JAMA Psychiatry, Locher et al3 examine the evidence for selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine inhibitors (SNRIs) for children and adolescents with anxiety disorders, depressive disorders, obsessive-compulsive disorder, and posttraumatic stress disorder. To date, most reviews and meta-analyses have been focused on one or other disorder. Having the information gathered together in one review is helpful, particularly as there is a high rate of comorbidity between these disorders. Based on 36 studies with 6778 participants, the authors found modest effects sizes (Hedges g) from medication, ranging from 0.56 (95% CI, 0.40-0.72) for anxiety disorders through 0.39 (95% CI, 0.25-0.54) for obsessive-compulsive disorder to 0.20 (95% CI, 0.13-0.27) for depressive disorders. There was only 1 study showing no effect in posttraumatic stress disorder. Overall, the effect size was small (g = 0.32; 95% CI, 0.25-0.40).

    更新日期:2017-10-06
  • Could Lithium in Drinking Water Reduce the Incidence of Dementia?
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01
    John J. McGrath, Michael Berk

    Now more than ever, the research community should be concentrating on finding ways to reduce the incidence of dementia. The population is aging, and the number of individuals affected by dementia remains a major public health challenge. The reality is that we have no effective treatments for dementia. In the absence of treatments to cure the disorder (or even reduce the associated burden by delaying onset or reducing disability), the prevention of dementia must be a priority research topic. Modifiable risk factors are associated with dementia1 (eg, diabetes and attendant behavioral risks, such as diet and physical activity); these risk factors are important but complex targets for intervention. However, as with many neurologic and psychiatric disorders, we have a scant appreciation of the environmental risk factors that contribute to dementia risk. There is an urgent need to generate new candidate risk factors for dementia. In contrast to genetics, for which there are now cost-efficient, high-throughput screening methods that can generate genetic candidates, epidemiology relies on a mix of creative researchers and access to suitable databases that contain the variables of interest. Epidemiologists are envious of our colleagues in genetics, in which the search space for risk variants is more tractable and bounded.

    更新日期:2017-10-06
  • Highlights
    JAMA Psychiatry (IF 15.307) Pub Date : 2017-10-01

    Binge eating disorder is the most common eating disorder worldwide, and cognitive behavioral therapy is the treatment of choice for this condition. Thus, it is important to know the efficacy of an internet-based delivery of this intervention, which would make it more readily available. de Zwaan and colleagues enrolled 178 adult individuals with binge eating problems in a prospective, multicenter, randomized, noninferiority clinical trial to examine the efficacy of face-to-face vs Internet-based cognitive behavioral therapy. Symptoms of binge eating improved faster and significantly more with face-to-face relative to internet-based cognitive behavioral therapy.

    更新日期:2017-10-06
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
化学 · 材料 期刊列表